Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Immutep Limited logo — The global leader in developing LAG-3 therapeutics (ASX: IMM...

Immutep Limited

The global leader in developing LAG-3 therapeutics (ASX: IMM, NASDAQ: IMMP)

Founded 1987 Australia Australia 49 employees Post Ipo Equity Total: $108.65M Biotechnology, Health Care +1

General Information

Company Name Immutep Limited
Founded Year 1987
Location Australia Australia +1
Employees 49
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Post Ipo Equity
Social

Get notified when Immutep Limited moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Immutep Limited

**Immutep Limited** is a late-stage clinical biotechnology company that specializes in developing novel LAG-3 immunotherapies to combat cancer and autoimmune diseases. The company's innovative approach involves leveraging the unique capabilities of Lymphocyte Activation Gene-3 (LAG-3) to modulate the immune response. Their product portfolio includes eftilagimod alpha, a proprietary soluble LAG-3 protein, and MHC Class II agonist in oncology, as well as IMP761, the world's first LAG-3 agonist targeting the root causes of autoimmune diseases. Founded in **1987** and based in **Australia**, Immutep trades on the Australian Securities Exchange (ASX: IMM) and the NASDAQ (IMMP). The company continues to attract investments, with the most recent being a post-IPO equity investment on **2nd June 2023**. Immutep's dedication to delivering innovative treatment options to patients and maximizing value for shareholders makes it an attractive prospect for investors seeking opportunities in the **biotechnology**, **healthcare**, and **pharmaceutical** industries. With its cutting-edge approach to harnessing the potential of LAG-3, Immutep stands out as a global leader in developing therapeutics targeting key medical challenges.

Taxonomy: immunotherapy, oncology, clinical trials, autoimmune diseases, cancer therapeutics, immunostimulatory factor, therapeutic antibody, immune response modulation, immune control mechanism, LAG-3 agonist, MHC Class II agonist, ASX listed company, NASDAQ listed company

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• - 05 Jun 2024
Post-IPO Equity •••••• - 02 Jun 2023
Grant •••••• - 06 Sep 2022
Post-IPO Equity •••••• 3
Investor Investor
•••• •••• 		09 Jul 2019
Post-IPO Equity •••••• - 12 Mar 2018

Immutep Limited Alternatives & Competitors

Immutep Limited vs
Tallac Therapeutics
Tallac Therapeutics United States

Next generation immunotherapies for cancer patients: harnessing the power of innate and adaptive imm...

Debt Financing
18 employees
Biotechnology, Health Care
Compare Immutep Limited vs Tallac Therapeutics
Immutep Limited vs
Lyvgen Biopharma
Lyvgen Biopharma China

Lyvgen is a bio-pharmaceutical company focused on developing novel agonist therapeutic antibodies fo...

Series C
19 employees
Biopharma, Health Care
Compare Immutep Limited vs Lyvgen Biopharma
Immutep Limited vs
CymaBay Therapeutics
CymaBay Therapeutics United States

Dedicated to improving the lives of patients with liver diseases

Acquired
32 employees
Biopharma, Biotechnology
Compare Immutep Limited vs CymaBay Therapeutics

FAQ About Immutep Limited

The global leader in developing LAG-3 therapeutics (ASX: IMM, NASDAQ: IMMP)
Immutep Limited was founded in 1987.
Immutep Limited is headquartered in Australia.
Immutep Limited operates in the following industries: Biotechnology, Health Care, Pharmaceutical.
Immutep Limited has approximately 49 employees.
Immutep Limited has completed 5 funding rounds, raising a total of $108.65M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to Immutep Limited include Tallac Therapeutics, Lyvgen Biopharma, CymaBay Therapeutics, ImmuNext, VentiRx Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Immutep Limited and Tallac Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Immutep Limited and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes